{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T06:58:31Z","timestamp":1794812311760,"version":"4.9.1"},"reference-count":207,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"DOI":"10.1186\/s13098-025-01623-w","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T17:35:21Z","timestamp":1739813721000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["GLP-1-based therapies for type 2 diabetes: from single, dual and triple agonists to endogenous GLP-1 production and L-cell differentiation"],"prefix":"10.1186","volume":"17","author":[{"given":"Maedeh","family":"Movahednasab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Dianat-Moghadam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana","family":"Khodadad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Nedaeinia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeid","family":"Safabakhsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Ferns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasoul","family":"Salehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"key":"1623_CR1","doi-asserted-by":"crossref","unstructured":"Webber S. International Diabetes Federation. Diabetes Research and Clinical Practice. vol. 102, 2013. p. 147\u2013148.","DOI":"10.1016\/j.diabres.2013.10.013"},{"issue":"7","key":"1623_CR2","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41574-018-0016-2","volume":"14","author":"A Andersen","year":"2018","unstructured":"Andersen A, Lund A, Knop FK, Vilsb\u00f8ll T. Glucagon-like peptide 1 in health and disease. Nat Rev Endocrinol. 2018;14(7):390\u2013403.","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"1623_CR3","doi-asserted-by":"publisher","first-page":"124","DOI":"10.2337\/diabetes.52.1.124","volume":"52","author":"J Buteau","year":"2003","unstructured":"Buteau J, Foisy S, Joly E, Prentki M. Glucagon-like peptide 1 induces pancreatic \u03b2-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes. 2003;52(1):124\u201332.","journal-title":"Diabetes"},{"issue":"8","key":"1623_CR4","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.2337\/db09-0063","volume":"58","author":"M Cornu","year":"2009","unstructured":"Cornu M, Yang JY, Jaccard E, Poussin C, Widmann C, Thorens B. Glucagon-like peptide-1 protects \u03b2-cells against apoptosis by increasing the activity of an Igf-2\/Igf-1 receptor autocrine loop. Diabetes. 2009;58(8):1816.","journal-title":"Diabetes"},{"issue":"11","key":"1623_CR5","doi-asserted-by":"publisher","first-page":"4397","DOI":"10.1210\/en.2002-220405","volume":"143","author":"L Farilla","year":"2002","unstructured":"Farilla L, Hongxiang H, Bertolotto C, Kang E, Bulotta A, Mario UDI, et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology. 2002;143(11):4397\u2013408.","journal-title":"Endocrinology"},{"issue":"10","key":"1623_CR6","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.2337\/diabetes.50.10.2237","volume":"50","author":"J Buteau","year":"2001","unstructured":"Buteau J, Foisy S, Rhodes CJ, Carpenter L, Biden TJ, Prentki M. Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation. Diabetes. 2001;50(10):2237\u201343.","journal-title":"Diabetes"},{"issue":"1","key":"1623_CR7","doi-asserted-by":"publisher","first-page":"124","DOI":"10.2337\/diabetes.52.1.124","volume":"52","author":"J Buteau","year":"2003","unstructured":"Buteau J, Foisy S, Joly E, Prentki M. Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes. 2003;52(1):124\u201332.","journal-title":"Diabetes"},{"issue":"13","key":"1623_CR8","doi-asserted-by":"publisher","first-page":"8723","DOI":"10.1074\/jbc.M706105200","volume":"283","author":"Z Liu","year":"2008","unstructured":"Liu Z, Habener JF. Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation. J Biol Chem. 2008;283(13):8723\u201335.","journal-title":"J Biol Chem"},{"issue":"4","key":"1623_CR9","first-page":"920","volume":"273","author":"N Imery\u00fcz","year":"1997","unstructured":"Imery\u00fcz N, Ye\u01e7en B\u00c7, Bozkurt A, Co\u015fkun T, Villanueva-Penacarrillo ML, Ulusoy NB. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol. 1997;273(4):920.","journal-title":"Am J Physiol"},{"issue":"2","key":"1623_CR10","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1210\/jc.2017-02006","volume":"103","author":"MA Halim","year":"2018","unstructured":"Halim MA, Degerblad M, Sundbom M, Karlbom U, Holst JJ, Webb DL, et al. Glucagon-like peptide-1 inhibits prandial gastrointestinal motility through myenteric neuronal mechanisms in humans. J Clin Endocrinol Metab. 2018;103(2):575\u201385. https:\/\/doi.org\/10.1210\/jc.2017-02006.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"1623_CR11","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1007\/s00125-008-1149-y","volume":"51","author":"J De Heer","year":"2008","unstructured":"De Heer J, Rasmussen C, Coy DH, Holst JJ. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia. 2008;51(12):2263\u201370.","journal-title":"Diabetologia"},{"issue":"1","key":"1623_CR12","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/BF02427280","volume":"29","author":"M Nauck","year":"1986","unstructured":"Nauck M, St\u00f6ckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29(1):46\u201352.","journal-title":"Diabetologia"},{"issue":"9","key":"1623_CR13","doi-asserted-by":"publisher","first-page":"E774","DOI":"10.1152\/ajpendo.00496.2015","volume":"310","author":"BA Aulinger","year":"2016","unstructured":"Aulinger BA, Vahl TP, Prigeon RL, D\u2019Alessio DA, Elder DA. The incretin effect in obese adolescents with and without type 2 diabetes: impaired or intact? Am J Physiol Endocrinol Metab. 2016;310(9):E774\u201381.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"1623_CR14","doi-asserted-by":"publisher","first-page":"154415","DOI":"10.1016\/j.metabol.2020.154415","volume":"114","author":"E Grespan","year":"2021","unstructured":"Grespan E, Giorgino T, Natali A, Ferrannini E, Mari A. Different mechanisms of GIP and GLP-1 action explain their different therapeutic efficacy in type 2 diabetes. Metabolism. 2021;114:154415.","journal-title":"Metabolism"},{"issue":"8","key":"1623_CR15","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.1210\/jcem.86.8.7750","volume":"86","author":"MB Toft-Nielsen","year":"2001","unstructured":"Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab. 2001;86(8):3717\u201323.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1623_CR16","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1210\/jc.2002-021053","volume":"88","author":"T Vilsb\u00f8ll","year":"2003","unstructured":"Vilsb\u00f8ll T, Agers\u00f8 H, Krarup T, Holst JJ. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab. 2003;88(1):220\u20134. https:\/\/doi.org\/10.1210\/jc.2002-021053.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1623_CR17","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s00125-013-2841-0","volume":"56","author":"S Calanna","year":"2013","unstructured":"Calanna S, Christensen M, Holst JJ, Laferr\u00e8re B, Gluud LL, Vilsb\u00f8ll T, et al. Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Diabetologia. 2013;56(5):965.","journal-title":"Diabetologia"},{"issue":"6","key":"1623_CR18","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1210\/jc.2002-021873","volume":"88","author":"T Vilsb\u00f8ll","year":"2003","unstructured":"Vilsb\u00f8ll T, Krarup T, Sonne J, Madsbad S, V\u00f8lund A, Juul AG, et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab. 2003;88(6):2706\u201313.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1623_CR19","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.3390\/ijms21062032","volume":"21","author":"T Takahashi","year":"2020","unstructured":"Takahashi T, Shiraishi A. Stem cell signaling pathways in the small intestine. Int J Mol Sci. 2020;21(6):2032.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1623_CR20","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nmeth.2737","volume":"11","author":"X Yin","year":"2014","unstructured":"Yin X, Farin HF, Van Es JH, Clevers H, Langer R, Karp JM. Niche-independent high-purity cultures of Lgr5+ intestinal stem cells and their progeny. Nat Methods. 2014;11(1):106.","journal-title":"Nat Methods"},{"issue":"20","key":"1623_CR21","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1101\/gad.1353905","volume":"19","author":"NF Shroyer","year":"2005","unstructured":"Shroyer NF, Wallis D, Venken KJT, Bellen HJ, Zoghbi HY. Gfi1 functions downstream of Math1 to control intestinal secretory cell subtype allocation and differentiation. Genes Dev. 2005;19(20):2412\u20137.","journal-title":"Genes Dev"},{"issue":"2","key":"1623_CR22","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1053\/j.gastro.2007.05.020","volume":"133","author":"Y Mori-Akiyama","year":"2007","unstructured":"Mori-Akiyama Y, van den Born M, van Es JH, Hamilton SR, Adams HP, Zhang J, et al. SOX9 is required for the differentiation of paneth cells in the intestinal epithelium. Gastroenterology. 2007;133(2):539\u201346.","journal-title":"Gastroenterology"},{"issue":"11","key":"1623_CR23","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1242\/dev.129.11.2619","volume":"129","author":"JP Katz","year":"2002","unstructured":"Katz JP, Perreault N, Goldstein BG, Lee CS, Labosky PA, Yang VW, et al. The zinc-finger transcription factor Klf4 is required for terminal differentiation of goblet cells in the colon. Development. 2002;129(11):2619\u201328.","journal-title":"Development"},{"issue":"5","key":"1623_CR24","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.cell.2018.12.029","volume":"176","author":"H Gehart","year":"2019","unstructured":"Gehart H, van Es JH, Hamer K, Beumer J, Kretzschmar K, Dekkers JF, et al. Identification of enteroendocrine regulators by real-time single-cell differentiation mapping. Cell. 2019;176(5):1158\u2013117316.","journal-title":"Cell"},{"issue":"8","key":"1623_CR25","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/s41556-018-0143-y","volume":"20","author":"J Beumer","year":"2018","unstructured":"Beumer J, Artegiani B, Post Y, Reimann F, Gribble F, Nguyen TN, et al. Enteroendocrine cells switch hormone expression along the crypt-to-villus BMP signalling gradient. Nat Cell Biol. 2018;20(8):909\u201316.","journal-title":"Nat Cell Biol"},{"key":"1623_CR26","doi-asserted-by":"publisher","first-page":"154031","DOI":"10.1016\/j.metabol.2019.154031","volume":"103","author":"MA Nauck","year":"2020","unstructured":"Nauck MA. The rollercoaster history of using physiological and pharmacological properties of incretin hormones to develop diabetes medications with a convincing benefit\u2013risk relationship. Metabolism. 2020;103:154031. https:\/\/doi.org\/10.1016\/j.metabol.2019.154031.","journal-title":"Metabolism"},{"issue":"6","key":"1623_CR27","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.2337\/db06-1033","volume":"56","author":"G Xu","year":"2007","unstructured":"Xu G, Kaneto H, Laybutt DR, Duvivier-Kali VF, Trivedi N, Suzuma K, et al. Downregulation of GLP-1 and GIP receptor expression by hyperglycemia possible contribution to impaired incretin effects in diabetes. Diabetes. 2007;56(6):1551\u20138. https:\/\/doi.org\/10.2337\/db06-1033.","journal-title":"Diabetes"},{"issue":"7","key":"1623_CR28","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.2337\/db14-1751","volume":"64","author":"K Faerch","year":"2015","unstructured":"Faerch K, Torekov SS, Vistisen D, Johansen NB, Witte DR, Jonsson A, et al. GLP-1 response to oral glucose is reduced in prediabetes, screen-detected type 2 diabetes, and obesity and influenced by sex: the ADDITION-PRO Study. Diabetes. 2015;64(7):2513\u201325. https:\/\/doi.org\/10.2337\/db14-1751.","journal-title":"Diabetes"},{"issue":"140","key":"1623_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2022.155375","volume":"1","author":"JD Watkins","year":"2023","unstructured":"Watkins JD, Carter S, Atkinson G, Koumanov F, Betts JA, Holst JJ, et al. Glucagon-like peptide-1 secretion in people with versus without type 2 diabetes: a systematic review and meta-analysis of cross-sectional studies. Metabolism. 2023;1(140): 155375.","journal-title":"Metabolism"},{"issue":"1","key":"1623_CR30","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jphs.2020.11.005","volume":"145","author":"F Tian","year":"2021","unstructured":"Tian F, Wang X, Ni H, Feng X, Yuan X, Huang Q. The ginsenoside metabolite compound K stimulates glucagon-like peptide-1 secretion in NCI-H716 cells by regulating the RhoA\/ROCKs\/YAP signaling pathway and cytoskeleton formation. J Pharmacol Sci. 2021;145(1):88\u201396.","journal-title":"J Pharmacol Sci"},{"issue":"13","key":"1623_CR31","doi-asserted-by":"publisher","first-page":"6660","DOI":"10.3390\/ijms22136660","volume":"22","author":"A Filippello","year":"2021","unstructured":"Filippello A, Di Mauro S, Scamporrino A, Malaguarnera R, Torrisi SA, Leggio GM, et al. High glucose exposure impairs L-cell differentiation in intestinal organoids: molecular mechanisms and clinical implications. Int J Mol Sci. 2021;22(13):6660.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1623_CR32","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41366-020-00694-1","volume":"45","author":"C Osinski","year":"2020","unstructured":"Osinski C, Le Gl\u00e9au L, Poitou C, de Toro-Martin J, Genser L, Fradet M, et al. Type 2 diabetes is associated with impaired jejunal enteroendocrine GLP-1 cell lineage in human obesity. Int J Obes. 2020;45(1):170\u201383.","journal-title":"Int J Obes"},{"issue":"1","key":"1623_CR33","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41419-020-03366-0","volume":"12","author":"J Wang","year":"2021","unstructured":"Wang J, Zhao D, Ding CZ, Guo F, Wu LN, Huang FJ, et al. MicroRNA-194: a novel regulator of glucagon-like peptide-1 synthesis in intestinal L cells. Cell Death Dis. 2021;12(1):113.","journal-title":"Cell Death Dis"},{"issue":"8","key":"1623_CR34","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/BF00401145","volume":"36","author":"MA Nauck","year":"1993","unstructured":"Nauck MA, Kleine N, \u00d8rskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7\u201336 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36(8):741\u20134.","journal-title":"Diabetologia"},{"issue":"9","key":"1623_CR35","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1111\/j.1464-5491.2010.03020.x","volume":"27","author":"RE Ratner","year":"2010","unstructured":"Ratner RE, Rosenstock J, Boka G. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. Diabetic Med. 2010;27(9):1024.","journal-title":"Diabetic Med"},{"issue":"18","key":"1623_CR36","doi-asserted-by":"publisher","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","volume":"58","author":"J Lau","year":"2015","unstructured":"Lau J, Bloch P, Sch\u00e4ffer L, Pettersson I, Spetzler J, Kofoed J, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370\u201380.","journal-title":"J Med Chem"},{"issue":"12","key":"1623_CR37","doi-asserted-by":"publisher","first-page":"4810","DOI":"10.1210\/jc.2008-1518","volume":"93","author":"JE Matthews","year":"2008","unstructured":"Matthews JE, Stewart MW, De Boever EH, Dobbins RL, Hodge RJ, Walker SE, et al. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008;93(12):4810\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"1623_CR38","unstructured":"Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes."},{"issue":"13","key":"1623_CR39","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.2146\/ajhp120168","volume":"70","author":"GJ Ryan","year":"2013","unstructured":"Ryan GJ, Moniri NH, Smiley DD. Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus. Am J Health Syst Pharm. 2013;70(13):1123\u201331.","journal-title":"Am J Health Syst Pharm"},{"key":"1623_CR40","doi-asserted-by":"crossref","unstructured":"Buckley ST, B\u00e6kdal TA, Vegge A, Maarbjerg SJ, Pyke C, Ahnfelt-R\u00f8nne J, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med. 2018;10(468).","DOI":"10.1126\/scitranslmed.aar7047"},{"issue":"5","key":"1623_CR41","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.cmet.2006.10.001","volume":"4","author":"B Yusta","year":"2006","unstructured":"Yusta B, Baggio LL, Estall JL, Koehler JA, Holland DP, Li H, et al. GLP-1 receptor activation improves \u03b2 cell function and survival following induction of endoplasmic reticulum stress. Cell Metab. 2006;4(5):391\u2013406.","journal-title":"Cell Metab"},{"key":"1623_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117648","volume":"252","author":"J Fu","year":"2020","unstructured":"Fu J, Nchambi KM, Wu H, Luo X, An X, Liu D. Liraglutide protects pancreatic \u03b2 cells from endoplasmic reticulum stress by upregulating MANF to promote autophagy turnover. Life Sci. 2020;252: 117648.","journal-title":"Life Sci"},{"issue":"4","key":"1623_CR43","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","volume":"6","author":"RE Pratley","year":"2018","unstructured":"Pratley RE, Aroda VR, Lingvay I, L\u00fcdemann J, Andreassen C, Navarria A, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4):275\u201386.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"1623_CR44","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653\u201362.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"1623_CR45","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311.","journal-title":"N Engl J Med"},{"issue":"19","key":"1623_CR46","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344.","journal-title":"N Engl J Med"},{"issue":"10193","key":"1623_CR47","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet (London, England). 2019;394(10193):121\u201330.","journal-title":"Lancet (London, England)."},{"issue":"15","key":"1623_CR48","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2017.14752","volume":"318","author":"M Davies","year":"2017","unstructured":"Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OKH, Jabbour S, Rosenstock J. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. JAMA. 2017;318(15):1460.","journal-title":"JAMA"},{"issue":"9","key":"1623_CR49","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841\u201351. https:\/\/doi.org\/10.1056\/NEJMoa1901118.","journal-title":"N Engl J Med"},{"issue":"1","key":"1623_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-014-0142-7","volume":"13","author":"FK Saraiva","year":"2014","unstructured":"Saraiva FK, Sposito AC. Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists. Cardiovasc Diabetol. 2014;13(1):1\u201311. https:\/\/doi.org\/10.1186\/s12933-014-0142-7.","journal-title":"Cardiovasc Diabetol"},{"key":"1623_CR51","doi-asserted-by":"crossref","unstructured":"Wong C, Lee MH, Yaow CYL, Chin YH, Goh XL, Ng CH, et al. Glucagon-like peptide-1 receptor agonists for non-alcoholic fatty liver disease in type 2 diabetes: a meta-analysis. Front Endocrinol (Lausanne). 2021;12.","DOI":"10.3389\/fendo.2021.609110"},{"issue":"6","key":"1623_CR52","doi-asserted-by":"publisher","first-page":"4544","DOI":"10.3390\/cimb45060288","volume":"45","author":"A Petrovic","year":"2023","unstructured":"Petrovic A, Igrec D, Rozac K, Bojanic K, Kuna L, Kolaric TO, et al. The role of GLP1-RAs in direct modulation of lipid metabolism in hepatic tissue as determined using in vitro models of NAFLD. Curr Issues Mol Biol. 2023;45(6):4544\u201356.","journal-title":"Curr Issues Mol Biol"},{"issue":"8","key":"1623_CR53","doi-asserted-by":"publisher","first-page":"5238","DOI":"10.1007\/s12010-023-04505-x","volume":"195","author":"S Zheng","year":"2023","unstructured":"Zheng S, Huang H, Chen H, Liu Y. Glp-1 receptor agonists regulate the progression of diabetes mellitus complicated with fatty liver by down-regulating the expression of genes related to lipid metabolism. Appl Biochem Biotechnol. 2023;195(8):5238\u201351. https:\/\/doi.org\/10.1007\/s12010-023-04505-x.","journal-title":"Appl Biochem Biotechnol"},{"issue":"9","key":"1623_CR54","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1056\/NEJMoa1616011","volume":"377","author":"JFE Mann","year":"2017","unstructured":"Mann JFE, \u00d8rsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377(9):839\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1616011.","journal-title":"N Engl J Med"},{"issue":"8","key":"1623_CR55","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","volume":"6","author":"KR Tuttle","year":"2018","unstructured":"Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 2018;6(8):605\u201317.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"1623_CR56","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1152\/ajprenal.00729.2010","volume":"301","author":"RO Crajoinas","year":"2011","unstructured":"Crajoinas RO, Oricchio FT, Pessoa TD, Pacheco BPM, Lessa LMA, Malnic G, et al. Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. Am J Physiol Ren Physiol. 2011;301(2):355\u201363. https:\/\/doi.org\/10.1152\/ajprenal.00729.2010.","journal-title":"Am J Physiol Ren Physiol."},{"issue":"12","key":"1623_CR57","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1111\/dom.12382","volume":"16","author":"J Reusch","year":"2014","unstructured":"Reusch J, Stewart MW, Perkins CM, Cirkel DT, Ye J, Perry CR, et al. Diabetes Obes Metab. 2014;16(12):1257\u201364.","journal-title":"Diabetes Obes Metab"},{"key":"1623_CR58","doi-asserted-by":"crossref","unstructured":"Finan B, Ma T, Ottaway N, M\u00fcller TD, Habegger KM, Heppner KM, et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med. 2013;5(209).","DOI":"10.1126\/scitranslmed.3007218"},{"issue":"10","key":"1623_CR59","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1111\/dom.13024","volume":"19","author":"C Schmitt","year":"2017","unstructured":"Schmitt C, Portron A, Jadidi S, Sarkar N, DiMarchi R. Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide\/glucagon-like peptide-1 agonist RG7697 in people with type 2 diabetes mellitus. Diabetes Obes Metab. 2017;19(10):1436\u201345.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"1623_CR60","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.cmet.2017.07.011","volume":"26","author":"JP Frias","year":"2017","unstructured":"Frias JP, Bastyr EJ, Vignati L, Tsch\u00f6p MH, Schmitt C, Owen K, et al. The sustained effects of a dual GIP\/GLP-1 receptor agonist, NNC0090\u20132746, in patients with type 2 diabetes. Cell Metab. 2017;26(2):343-352E2.","journal-title":"Cell Metab"},{"key":"1623_CR61","unstructured":"Of H, Information P, Approval IUS, Drugs S, Disorder MD, Changes RM, et al. See full prescribing information for complete boxed warning. 1987;1\u201325."},{"key":"1623_CR62","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","volume":"18","author":"T Coskun","year":"2018","unstructured":"Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018;18:3\u201314.","journal-title":"Mol Metab."},{"issue":"10160","key":"1623_CR63","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","volume":"392","author":"JP Frias","year":"2018","unstructured":"Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018;392(10160):2180\u201393.","journal-title":"Lancet"},{"issue":"6","key":"1623_CR64","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1111\/dom.13979","volume":"22","author":"JP Frias","year":"2020","unstructured":"Frias JP, Nauck MA, Van J, Benson C, Bray R, Cui X, et al. Efficacy and tolerability of tirzepatide, a dual glucose\u2010dependent insulinotropic peptide and glucagon\u2010like peptide\u20101 receptor agonist in patients with type 2 diabetes: a 12\u2010week, randomized, double\u2010blind, placebo\u2010controlled study to evaluate different dose\u2010escalation regimens. Diabetes Obes Metab. 2020;22(6):938.","journal-title":"Diabetes Obes Metab"},{"issue":"10295","key":"1623_CR65","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","volume":"398","author":"J Rosenstock","year":"2021","unstructured":"Rosenstock J, Wysham C, Fr\u00edas JP, Kaneko S, Lee CJ, Fern\u00e1ndez Land\u00f3 L, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143\u201355.","journal-title":"Lancet"},{"issue":"6","key":"1623_CR66","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, P\u00e9rez Manghi FC, Fern\u00e1ndez Land\u00f3 L, Bergman BK, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503\u201315.","journal-title":"N Engl J Med"},{"issue":"10300","key":"1623_CR67","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","volume":"398","author":"B Ludvik","year":"2021","unstructured":"Ludvik B, Giorgino F, J\u00f3dar E, Frias JP, Fern\u00e1ndez Land\u00f3 L, Brown K, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet (London, England). 2021;398(10300):583\u201398.","journal-title":"Lancet (London, England)."},{"issue":"10313","key":"1623_CR68","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","volume":"398","author":"S Del Prato","year":"2021","unstructured":"Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811\u201324. https:\/\/doi.org\/10.1016\/S0140-6736(21)02188-7.","journal-title":"Lancet"},{"issue":"9","key":"1623_CR69","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S2213-8587(22)00188-7","volume":"10","author":"N Inagaki","year":"2022","unstructured":"Inagaki N, Takeuchi M, Oura T, Imaoka T, Seino Y. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022;10(9):623\u201333.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10295","key":"1623_CR70","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","volume":"398","author":"J Rosenstock","year":"2021","unstructured":"Rosenstock J, Wysham C, Frias JP, Kaneko S, Lee CJ, Lando LF, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143\u201355.","journal-title":"Lancet"},{"issue":"10313","key":"1623_CR71","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","volume":"398","author":"S Del Prato","year":"2021","unstructured":"Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet (London, England). 2021;398(10313):1811\u201324.","journal-title":"Lancet (London, England)."},{"issue":"6","key":"1623_CR72","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1001\/jama.2022.0078","volume":"327","author":"D Dahl","year":"2022","unstructured":"Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022;327(6):534\u201345.","journal-title":"JAMA"},{"issue":"1","key":"1623_CR73","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/dom.14553","volume":"24","author":"JM Wilson","year":"2022","unstructured":"Wilson JM, Lin Y, Luo MJ, Considine G, Cox AL, Bowsman LM, et al. The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: a post hoc analysis. Diabetes Obes Metab. 2022;24(1):148\u201353.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"1623_CR74","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1111\/dom.14174","volume":"22","author":"JM Wilson","year":"2020","unstructured":"Wilson JM, Nikooienejad A, Robins DA, Roell WC, Riesmeyer JS, Haupt A, et al. The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes. Diabetes Obes Metab. 2020;22(12):2451\u20139.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"1623_CR75","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","volume":"10","author":"HJL Heerspink","year":"2022","unstructured":"Heerspink HJL, Sattar N, Pavo I, Haupt A, Duffin KL, Yang Z, et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022;10(11):774\u201385.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1623_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2023\/5891532","volume":"2023","author":"Z Ma","year":"2023","unstructured":"Ma Z, Jin K, Yue M, Chen X, Chen J. Research progress on the GIP\/GLP-1 receptor coagonist tirzepatide, a rising star in type 2 diabetes. J Diabetes Res. 2023;2023:1\u20138.","journal-title":"J Diabetes Res"},{"key":"1623_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2023.171003","volume":"165","author":"A Novikoff","year":"2023","unstructured":"Novikoff A, M\u00fcller TD. The molecular pharmacology of glucagon agonists in diabetes and obesity. Peptides. 2023;165: 171003.","journal-title":"Peptides"},{"issue":"4","key":"1623_CR78","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.2337\/db12-0797","volume":"62","author":"TM Tan","year":"2013","unstructured":"Tan TM, Field BCT, McCullough KA, Troke RC, Chambers ES, Salem V, et al. Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. Diabetes. 2013;62(4):1131\u20138.","journal-title":"Diabetes"},{"issue":"6","key":"1623_CR79","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.2337\/db17-1331","volume":"67","author":"SS Shankar","year":"2018","unstructured":"Shankar SS, Shankar RR, Mixson LA, Miller DL, Pramanik B, O\u2019Dowd AK, et al. Native oxyntomodulin has significant glucoregulatory effects independent of weight loss in obese humans with and without type 2 diabetes. Diabetes. 2018;67(6):1105\u201312.","journal-title":"Diabetes"},{"issue":"8","key":"1623_CR80","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1111\/dom.13212","volume":"20","author":"R Elvert","year":"2018","unstructured":"Elvert R, Herling AW, Bossart M, Weiss T, Zhang B, Wenski P, et al. Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: a comparative study between mice and non-human primates. Diabetes Obes Metab. 2018;20(8):1836\u201351.","journal-title":"Diabetes Obes Metab"},{"key":"1623_CR81","doi-asserted-by":"publisher","DOI":"10.2337\/db21-682-P","author":"Y Chen","year":"2021","unstructured":"Chen Y, Mezo A, Coskun T, Song M, RoellBokvist WCKB, et al. 682-P: Novel dual glucagon and glucagon-like peptide-1 receptor agonist LY3305677 improves glucose control, reduces body weight, and increases energy expenditure in mice. Diabetes. 2021. https:\/\/doi.org\/10.2337\/db21-682-P.","journal-title":"Diabetes"},{"issue":"12","key":"1623_CR82","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/dom.12735","volume":"18","author":"SJ Henderson","year":"2016","unstructured":"Henderson SJ, Konkar A, Hornigold DC, Trevaskis JL, Jackson R, Fritsch Fredin M, et al. Robust anti-obesity and metabolic effects of a dual GLP-1\/glucagon receptor peptide agonist in rodents and non-human primates. Diabetes Obes Metab. 2016;18(12):1176\u201390.","journal-title":"Diabetes Obes Metab"},{"issue":"10140","key":"1623_CR83","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1016\/S0140-6736(18)30726-8","volume":"391","author":"P Ambery","year":"2018","unstructured":"Ambery P, Parker VE, Stumvoll M, Posch MG, Heise T, Plum-Moerschel L, et al. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study. Lancet (London, England). 2018;391(10140):2607\u201318.","journal-title":"Lancet (London, England)"},{"key":"1623_CR84","doi-asserted-by":"publisher","unstructured":"Jain M, Tsai LF, Robertson D, Hirshberg B, Hockings P, Johansson L, et al. MEDI0382, a GLP\/glucagon receptor dual agonist, significantly reduces hepatic fat content in subjects with type 2 diabetes mellitus. Diabetes. 2018;67(1). https:\/\/doi.org\/10.2337\/db18-78-OR.","DOI":"10.2337\/db18-78-OR"},{"issue":"6","key":"1623_CR85","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.2337\/dc20-2151","volume":"44","author":"R Nahra","year":"2021","unstructured":"Nahra R, Wang T, Gadde KM, Oscarsson J, Stumvoll M, Jermutus L, et al. Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: a 54-week randomized phase 2b study. Diabetes Care. 2021;44(6):1433\u201342.","journal-title":"Diabetes Care"},{"issue":"66","key":"1623_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2022.101633","volume":"1","author":"T Zimmermann","year":"2022","unstructured":"Zimmermann T, Thomas L, Baader-Pagler T, Haebel P, Simon E, Reindl W, et al. BI 456906: discovery and preclinical pharmacology of a novel GCGR\/GLP-1R dual agonist with robust anti-obesity efficacy. Mol Metab. 2022;1(66): 101633.","journal-title":"Mol Metab"},{"issue":"7","key":"1623_CR87","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1111\/dom.15064","volume":"25","author":"R Yazawa","year":"2023","unstructured":"Yazawa R, Ishida M, Balavarca Y, Hennige AM. A randomized Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906, a dual glucagon receptor\/glucagon-like peptide-1 receptor agonist, in healthy Japanese men with overweight\/obesity. Diabetes Obes Metab. 2023;25(7):1973\u201384.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"1623_CR88","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1111\/dom.14948","volume":"25","author":"A Jungnik","year":"2023","unstructured":"Jungnik A, Arrubla Martinez J, Plum-M\u00f6rschel L, Kapitza C, Lamers D, Thamer C, et al. Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor\/glucagon-like peptide-1 receptor agonist BI 456906. Diabetes Obes Metab. 2023;25(4):1011\u201323.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"1623_CR89","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1007\/s00125-023-06053-9","volume":"67","author":"M Bl\u00fcher","year":"2023","unstructured":"Bl\u00fcher M, Rosenstock J, Hoefler J, Manuel R, Hennige AM. Dose\u2013response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon\/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. Diabetologia. 2023;67(3):470\u201382. https:\/\/doi.org\/10.1007\/s00125-023-06053-9.","journal-title":"Diabetologia"},{"key":"1623_CR90","doi-asserted-by":"crossref","unstructured":"Fuselier T, Mota de Sa P, Qadir MMF, Xu B, Allard C, Meyers MM, et al. Efficacy of glucagon-like peptide-1 and estrogen dual agonist in pancreatic islets protection and pre-clinical models of insulin-deficient diabetes. Cell Reports Med. 2022;3(4).","DOI":"10.1016\/j.xcrm.2022.100598"},{"key":"1623_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2023.171073","volume":"169","author":"J Xu","year":"2023","unstructured":"Xu J, Wang S, Wu H, Chen D, Han J, Lin Q. Engineering a potent and long-acting GLP-1\/Y2 receptor dual agonist as a multi-agonist therapy for diabetes and obesity. Peptides. 2023;169: 171073.","journal-title":"Peptides"},{"issue":"21","key":"1623_CR92","doi-asserted-by":"publisher","first-page":"12595","DOI":"10.1021\/acs.jmedchem.0c00736","volume":"63","author":"X Chen","year":"2020","unstructured":"Chen X, Fu J, Zhou F, Yang Q, Wang J, Feng H, et al. Stapled and xenopus glucagon-like peptide 1 (GLP-1)-based dual GLP-1\/gastrin receptor agonists with improved metabolic benefits in rodent models of obesity and diabetes. J Med Chem. 2020;63(21):12595\u2013613.","journal-title":"J Med Chem"},{"issue":"2","key":"1623_CR93","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1021\/acs.jmedchem.0c01783","volume":"64","author":"BT Milliken","year":"2021","unstructured":"Milliken BT, Elfers C, Chepurny OG, Chichura KS, Sweet IR, Borner T, et al. Design and evaluation of peptide dual-agonists of GLP-1 and NPY2 receptors for glucoregulation and weight loss with mitigated nausea and emesis. J Med Chem. 2021;64(2):1127\u201338.","journal-title":"J Med Chem"},{"key":"1623_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.103202","volume":"63","author":"Q Pan","year":"2021","unstructured":"Pan Q, Lin S, Li Y, Liu L, Li X, Gao X, et al. A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis. EBioMedicine. 2021;63: 103202.","journal-title":"EBioMedicine"},{"key":"1623_CR95","doi-asserted-by":"publisher","unstructured":"Boye K, Sapin H, Ling Poon J, Fernandez Lando L, Huh R, Wang M, et al. A 753-P: Tirzepatide improves HRQoL compared with insulin lispro in poorly controlled basal insulin-treated adults with long-standing T2D (SURPASS-6). Diabetes. 2023;72(Supplement_1). https:\/\/doi.org\/10.2337\/db23-753-P.","DOI":"10.2337\/db23-753-P"},{"issue":"6","key":"1623_CR96","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S2213-8587(22)00077-8","volume":"10","author":"T Battelino","year":"2022","unstructured":"Battelino T, Bergenstal RM, Rodr\u00edguez A, Fern\u00e1ndez Land\u00f3 L, Bray R, Tong Z, et al. Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 2022;10(6):407\u201317.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"1623_CR97","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/S2213-8587(22)00187-5","volume":"10","author":"T Kadowaki","year":"2022","unstructured":"Kadowaki T, Chin R, Ozeki A, Imaoka T, Ogawa Y. Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial. Lancet Diabetes Endocrinol. 2022;10(9):634\u201344.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"1623_CR98","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/s41591-023-02344-1","volume":"29","author":"L Gao","year":"2023","unstructured":"Gao L, Lee BW, Chawla M, Kim J, Huo L, Du L, et al. Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial. Nat Med. 2023;29(6):1500\u201310.","journal-title":"Nat Med"},{"key":"1623_CR99","doi-asserted-by":"publisher","first-page":"10402","DOI":"10.1016\/S0140-6736(23)01200-X","volume":"402","author":"WT Garvey","year":"2023","unstructured":"Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet (London, England). 2023;402:10402.","journal-title":"Lancet (London, England)."},{"issue":"8","key":"1623_CR100","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1111\/dom.14394","volume":"23","author":"M Schiavon","year":"2021","unstructured":"Schiavon M, Visentin R, G\u00f6bel B, Riz M, Cobelli C, Klabunde T, et al. Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon-like peptide-1\/glucagon receptor agonist SAR425899 in comparison with liraglutide. Diabetes Obes Metab. 2021;23(8):1795\u2013805.","journal-title":"Diabetes Obes Metab"},{"key":"1623_CR101","doi-asserted-by":"crossref","unstructured":"Di Prospero NA, Yee J, Frustaci ME, Samtani MN, Alba M, Fleck P. Efficacy and safety of glucagon-like peptide-1\/glucagon receptor co-agonist JNJ-64565111 in individuals with type 2 diabetes mellitus and obesity: a randomized dose-ranging study. Clin Obes. 2021;11(2).","DOI":"10.1111\/cob.12433"},{"issue":"1","key":"1623_CR102","doi-asserted-by":"publisher","first-page":"160","DOI":"10.2337\/dc23-1287","volume":"47","author":"B Zhang","year":"2024","unstructured":"Zhang B, Cheng Z, Chen J, Zhang X, Liu D, Jiang H, et al. Efficacy and safety of mazdutide in chinese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial. Diabetes Care. 2024;47(1):160\u20138. https:\/\/doi.org\/10.2337\/dc23-1287.","journal-title":"Diabetes Care"},{"issue":"10401","key":"1623_CR103","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","volume":"402","author":"J Rosenstock","year":"2023","unstructured":"Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529\u201344.","journal-title":"Lancet"},{"issue":"1","key":"1623_CR104","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.cmet.2021.12.005","volume":"34","author":"M Bossart","year":"2022","unstructured":"Bossart M, Wagner M, Elvert R, Evers A, H\u00fcbschle T, Kloeckener T, et al. Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1\/GIP\/GCG receptor triagonist. Cell Metab. 2022;34(1):59-74.e10.","journal-title":"Cell Metab"},{"issue":"9","key":"1623_CR105","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.cmet.2022.07.013","volume":"34","author":"T Coskun","year":"2022","unstructured":"Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9.","journal-title":"Cell Metab"},{"issue":"10366","key":"1623_CR106","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1016\/S0140-6736(22)02033-5","volume":"400","author":"S Urva","year":"2022","unstructured":"Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869\u201381.","journal-title":"Lancet"},{"issue":"17","key":"1623_CR107","doi-asserted-by":"publisher","first-page":"4360","DOI":"10.1111\/bph.15860","volume":"179","author":"S Zhao","year":"2022","unstructured":"Zhao S, Yan Z, Du Y, Li Z, Tang C, Jing L, et al. A GLP-1\/glucagon (GCG)\/CCK2 receptors tri-agonist provides new therapy for obesity and diabetes. Br J Pharmacol. 2022;179(17):4360\u201377.","journal-title":"Br J Pharmacol"},{"issue":"247","key":"1623_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.115036","volume":"5","author":"Y Yuan","year":"2023","unstructured":"Yuan Y, Yan Z, Lao Q, Jiang N, Wu S, Lu Q, et al. Discovery of a potent and long-acting Xenopus GLP-1-based GLP-1\/glucagon\/Y2 receptor triple agonist. Eur J Med Chem. 2023;5(247): 115036.","journal-title":"Eur J Med Chem"},{"key":"1623_CR109","doi-asserted-by":"crossref","unstructured":"Chichura KS, Elfers CT, Salameh TS, Kamat V, Chepurny OG, McGivney A, et al. A peptide triple agonist of GLP-1, neuropeptide Y1, and neuropeptide Y2 receptors promotes glycemic control and weight loss. Sci Rep. 2023;13(1).","DOI":"10.1038\/s41598-023-36178-1"},{"issue":"2","key":"1623_CR110","doi-asserted-by":"publisher","first-page":"E592","DOI":"10.1210\/clinem\/dgaa758","volume":"106","author":"N Rohmann","year":"2021","unstructured":"Rohmann N, Schlicht K, Geisler C, Hollstein T, Knappe C, Krause L, et al. Circulating sDPP-4 is increased in obesity and insulin resistance but is not related to systemic metabolic inflammation. J Clin Endocrinol Metab. 2021;106(2):E592-601.","journal-title":"J Clin Endocrinol Metab"},{"issue":"18","key":"1623_CR111","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.114.010389","volume":"130","author":"BM Scirica","year":"2014","unstructured":"Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130(18):1579\u201388.","journal-title":"Circulation"},{"issue":"3","key":"1623_CR112","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/bdd.2003","volume":"37","author":"Y Nakamaru","year":"2016","unstructured":"Nakamaru Y, Akahoshi F, Iijima H, Hisanaga N, Kume T. Tissue distribution of teneligliptin in rats and comparisons with data reported for other dipeptidyl peptidase-4 inhibitors. Biopharm Drug Dispos. 2016;37(3):142\u201355.","journal-title":"Biopharm Drug Dispos"},{"issue":"2","key":"1623_CR113","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.bbrc.2013.03.010","volume":"434","author":"M Nabeno","year":"2013","unstructured":"Nabeno M, Akahoshi F, Kishida H, Miyaguchi I, Tanaka Y, Ishii S, et al. A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site. Biochem Biophys Res Commun. 2013;434(2):191\u20136.","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"1623_CR114","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.pharep.2019.03.008","volume":"71","author":"G Argun-Kurum","year":"2019","unstructured":"Argun-Kurum G, Kaya-Dagistanli F, Ozturk M. DPP4 inhibitor induces beta cell regeneration and DDR-1 protein expression as an endocrine progenitor cell marker in neonatal STZ-diabetic rats. Pharmacol Reports. 2019;71(4):721\u201331.","journal-title":"Pharmacol Reports"},{"issue":"7","key":"1623_CR115","doi-asserted-by":"publisher","first-page":"E1163","DOI":"10.1210\/jc.2013-1029","volume":"98","author":"P Shah","year":"2013","unstructured":"Shah P, Ardestani A, Dharmadhikari G, Laue S, Schumann DM, Kerr-Conte J, et al. The DPP-4 inhibitor linagliptin restores \u03b2-cell function and survival in human isolated islets through GLP-1 stabilization. J Clin Endocrinol Metab. 2013;98(7):E1163\u201372. https:\/\/doi.org\/10.1210\/jc.2013-1029.","journal-title":"J Clin Endocrinol Metab"},{"key":"1623_CR116","doi-asserted-by":"crossref","unstructured":"Lajthia E, Bucheit JD, Nadpara PA, Dixon DL, Caldas LM, Murchie M, et al. Combination therapy with once-weekly glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a case series. Pharm Pract (Granada). 2019;17(4).","DOI":"10.18549\/PharmPract.2019.4.1588"},{"issue":"11","key":"1623_CR117","doi-asserted-by":"publisher","first-page":"3460","DOI":"10.2337\/dc13-0323","volume":"36","author":"PH Groop","year":"2013","unstructured":"Groop PH, Cooper ME, Perkovic V, Emser A, Woerle HJ, Von Eynatten M. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care. 2013;36(11):3460\u20138.","journal-title":"Diabetes Care"},{"key":"1623_CR118","doi-asserted-by":"crossref","unstructured":"Terawaki Y, Nomiyama T, Takahashi H, Tsutsumi Y, Murase K, Nagaishi R, et al. Efficacy of dipeptidyl peptidase-4 inhibitor linagliptin in patients with type 2 diabetes undergoing hemodialysis. Diabetol Metab Syndr. 2015;7(1).","DOI":"10.1186\/s13098-015-0043-2"},{"key":"1623_CR119","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.12659\/MSM.890989","volume":"20","author":"I Kanazawa","year":"2014","unstructured":"Kanazawa I, Tanaka KI, Sugimoto T. DPP-4 inhibitors improve liver dysfunction in type 2 diabetes mellitus. Med Sci Monit. 2014;20:1662.","journal-title":"Med Sci Monit"},{"issue":"2","key":"1623_CR120","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/ajhp\/62.2.173","volume":"62","author":"OG Kolterman","year":"2005","unstructured":"Kolterman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman MS, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Heal Pharm. 2005;62(2):173\u201381. https:\/\/doi.org\/10.1093\/ajhp\/62.2.173.","journal-title":"Am J Heal Pharm."},{"issue":"8","key":"1623_CR121","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1002\/jps.23648","volume":"102","author":"A Plum","year":"2013","unstructured":"Plum A, Jensen LB, Kristensen JB. In vitro protein binding of liraglutide in human plasma determined by reiterated stepwise equilibrium dialysis. J Pharm Sci. 2013;102(8):2882\u20138.","journal-title":"J Pharm Sci"},{"issue":"4","key":"1623_CR122","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00109-017-1508-6","volume":"95","author":"M Shigeto","year":"2017","unstructured":"Shigeto M, Cha CY, Rorsman P, Kaku K. A role of PLC\/PKC-dependent pathway in GLP-1-stimulated insulin secretion. J Mol Med (Berl). 2017;95(4):361\u20138.","journal-title":"J Mol Med (Berl)"},{"issue":"4","key":"1623_CR123","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1111\/bph.15603","volume":"179","author":"DI Brierley","year":"2022","unstructured":"Brierley DI, de Lartigue G. Reappraising the role of the vagus nerve in GLP-1-mediated regulation of eating. Br J Pharmacol. 2022;179(4):584\u201399. https:\/\/doi.org\/10.1111\/bph.15603.","journal-title":"Br J Pharmacol"},{"issue":"7","key":"1623_CR124","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1016\/j.cmet.2021.05.002","volume":"33","author":"D Borgmann","year":"2021","unstructured":"Borgmann D, Ciglieri E, Biglari N, Brandt C, Cremer AL, Backes H, et al. Gut-brain communication by distinct sensory neurons differently controls feeding and glucose metabolism. Cell Metab. 2021;33(7):1466\u201314827.","journal-title":"Cell Metab"},{"key":"1623_CR125","doi-asserted-by":"crossref","unstructured":"Gabery S, Salinas CG, Paulsen SJ, Ahnfelt-R\u00f8nne J, Alanentalo T, Baquero AF, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI insight. 2020;5(6).","DOI":"10.1172\/jci.insight.133429"},{"key":"1623_CR126","doi-asserted-by":"publisher","first-page":"1431292","DOI":"10.3389\/fendo.2024.1431292","volume":"15","author":"QK Liu","year":"2024","unstructured":"Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists. Front Endocrinol (Lausanne). 2024;15:1431292.","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"7","key":"1623_CR127","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.2337\/dc14-1984","volume":"38","author":"JJ Meier","year":"2015","unstructured":"Meier JJ, Rosenstock J, Hincelin-M\u00e9ry A, Roy-Duval C, Delfolie A, Coester HV, et al. Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial. Diabetes Care. 2015;38(7):1263\u201373.","journal-title":"Diabetes Care"},{"issue":"5","key":"1623_CR128","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.2337\/db10-0474","volume":"60","author":"MA Nauck","year":"2011","unstructured":"Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes. 2011;60(5):1561\u20135.","journal-title":"Diabetes"},{"key":"1623_CR129","doi-asserted-by":"publisher","first-page":"409","DOI":"10.4103\/ijmr.IJMR_802_15","volume":"146","author":"DD Chaudhari","year":"2017","unstructured":"Chaudhari DD, Singh R, Mallappa RH, Rokana N, Kaushik JK, Bajaj R, et al. Evaluation of casein & whey protein hydrolysates as well as milk fermentates from lactobacillus helveticus for expression of gut hormones. Indian J Med Res. 2017;146:409\u201319.","journal-title":"Indian J Med Res"},{"issue":"189","key":"1623_CR130","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.foodchem.2015.02.022","volume":"15","author":"AL Gillespie","year":"2015","unstructured":"Gillespie AL, Calderwood D, Hobson L, Green BD. Whey proteins have beneficial effects on intestinal enteroendocrine cells stimulating cell growth and increasing the production and secretion of incretin hormones. Food Chem. 2015;15(189):120\u20138.","journal-title":"Food Chem"},{"key":"1623_CR131","doi-asserted-by":"crossref","unstructured":"Modvig IM, Kuhre RE, Holst JJ. Peptone-mediated glucagon-like peptide-1 secretion depends on intestinal absorption and activation of basolaterally located calcium-sensing receptors. Physiol Rep. 2019;7(8).","DOI":"10.14814\/phy2.14056"},{"issue":"3","key":"1623_CR132","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1530\/JME-19-0260","volume":"64","author":"T Nakamura","year":"2020","unstructured":"Nakamura T, Harada K, Kamiya T, Takizawa M, K\u00fcppers J, Nakajima K, et al. Glutamine-induced signaling pathways via amino acid receptors in enteroendocrine L cell lines. J Mol Endocrinol. 2020;64(3):133\u201343.","journal-title":"J Mol Endocrinol"},{"issue":"588","key":"1623_CR133","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.bbrc.2021.12.043","volume":"15","author":"Y Osuga","year":"2022","unstructured":"Osuga Y, Harada K, Tsuboi T. Identification of a regulatory pathway of l-phenylalanine-induced GLP-1 secretion in the enteroendocrine L cells. Biochem Biophys Res Commun. 2022;15(588):118\u201324.","journal-title":"Biochem Biophys Res Commun"},{"key":"1623_CR134","doi-asserted-by":"crossref","unstructured":"Vineetha KK, Rao GM, Prabhu KA, Vinodchandran, Kavyashree, Marathe A, et al. Effect of L-tryptophan on intestinal glucagon like peptide-1(GLP-1) in streptozotocin (stz) induced diabetic rat model. Biomedicine. 2021;41(2):194\u20138.","DOI":"10.51248\/.v41i2.782"},{"issue":"7","key":"1623_CR135","doi-asserted-by":"publisher","first-page":"4513","DOI":"10.1074\/jbc.M112.402677","volume":"288","author":"M Oya","year":"2013","unstructured":"Oya M, Kitaguchi T, Pais R, Reimann F, Gribble F, Tsuboi T. The G protein-coupled receptor family C group 6 subtype A (GPRC6A) receptor is involved in amino acid-induced glucagon-like peptide-1 secretion from GLUTag cells. J Biol Chem. 2013;288(7):4513\u201321.","journal-title":"J Biol Chem"},{"issue":"12","key":"1623_CR136","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1007\/s00125-013-3037-3","volume":"56","author":"E Diakogiannaki","year":"2013","unstructured":"Diakogiannaki E, Pais R, Tolhurst G, Parker HE, Horscroft J, Rauscher B, et al. Oligopeptides stimulate glucagon-like peptide-1 secretion in mice through proton-coupled uptake and the calcium-sensing receptor. Diabetologia. 2013;56(12):2688\u201396.","journal-title":"Diabetologia"},{"key":"1623_CR137","doi-asserted-by":"crossref","unstructured":"Caron J, Domenger D, Dhulster P, Ravallec R, Cudennec B. Protein digestion-derived peptides and the peripheral regulation of food intake. Front Endocrinol (Lausanne). 2017;8.","DOI":"10.3389\/fendo.2017.00085"},{"key":"1623_CR138","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.nutres.2016.12.002","volume":"37","author":"M Kato","year":"2017","unstructured":"Kato M, Nakanishi T, Tani T, Tsuda T. Low-molecular fraction of wheat protein hydrolysate stimulates glucagon-like peptide-1 secretion in an enteroendocrine L cell line and improves glucose tolerance in rats. Nutr Res. 2017;37:37\u201345.","journal-title":"Nutr Res"},{"issue":"5","key":"1623_CR139","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1007\/s00125-004-1380-0","volume":"47","author":"JC Gevrey","year":"2004","unstructured":"Gevrey JC, Malapel M, Philippe J, Mithieux G, Chayvialle JA, Abello J, et al. Protein hydrolysates stimulate proglucagon gene transcription in intestinal endocrine cells via two elements related to cyclic AMP response element. Diabetologia. 2004;47(5):926\u201336.","journal-title":"Diabetologia"},{"key":"1623_CR140","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.biochi.2018.11.017","volume":"159","author":"S Ntika","year":"2019","unstructured":"Ntika S, Thombare K, Aryapoor M, Kristinsson H, Bergsten P, Krizhanovskii C. Oleate increase neutral lipid accumulation, cellular respiration and rescues palmitate-exposed GLP-1 secreting cells by reducing ceramide-induced ROS. Biochimie. 2019;159:23\u201335.","journal-title":"Biochimie"},{"key":"1623_CR141","doi-asserted-by":"crossref","unstructured":"Martchenko A, Oh RH, Wheeler SE, Gurges P, Chalmers JA, Brubaker PL. Suppression of circadian secretion of glucagon-like peptide-1 by the saturated fatty acid, palmitate. Acta Physiol. 2018;222(4).","DOI":"10.1111\/apha.13007"},{"issue":"1","key":"1623_CR142","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nm1168","volume":"11","author":"A Hirasawa","year":"2005","unstructured":"Hirasawa A, Tsumaya K, Awaji T, Katsuma S, Adachi T, Yamada M, et al. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med. 2005;11(1):90\u20134.","journal-title":"Nat Med"},{"issue":"4","key":"1623_CR143","doi-asserted-by":"publisher","first-page":"G617","DOI":"10.1152\/ajpgi.00312.2020","volume":"320","author":"Y Fujiwara","year":"2021","unstructured":"Fujiwara Y, Yamane S, Harada N, Ikeguchi-Ogura E, Usui R, Nakamura T, et al. Carbonic anhydrase 8 (CAR8) negatively regulates GLP-1 secretion from enteroendocrine cells in response to long-chain fatty acids. Am J Physiol Gastrointest Liver Physiol. 2021;320(4):G617\u201326.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"7","key":"1623_CR144","doi-asserted-by":"publisher","first-page":"E899","DOI":"10.1152\/ajpendo.00116.2012","volume":"303","author":"MA Poreba","year":"2012","unstructured":"Poreba MA, Dong CX, Li SK, Stahl A, Miner JH, Brubaker PL. Role of fatty acid transport protein 4 in oleic acid-induced glucagon-like peptide-1 secretion from murine intestinal L cells. Am J Physiol Endocrinol Metab. 2012;303(7):E899-907.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"4","key":"1623_CR145","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1210\/en.2010-1352","volume":"152","author":"R Iakoubov","year":"2011","unstructured":"Iakoubov R, Ahmed A, Lauffer LM, Bazinet RP, Brubaker PL. Essential role for protein kinase C\u03b6 in oleic acid-induced glucagon-like peptide-1 secretion in vivo in the rat. Endocrinology. 2011;152(4):1244\u201352.","journal-title":"Endocrinology"},{"issue":"5","key":"1623_CR146","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.2337\/db08-1237","volume":"58","author":"LM Lauffer","year":"2009","unstructured":"Lauffer LM, Iakoubov R, Brubaker PL. GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell. Diabetes. 2009;58(5):1058\u201366.","journal-title":"Diabetes"},{"key":"1623_CR147","doi-asserted-by":"crossref","unstructured":"Payahoo L, Khajebishak Y, Alivand MR, Soleimanzade H, Alipour S, Barzegari A, et al. Investigation the effect of oleoylethanolamide supplementation on the abundance of Akkermansia muciniphila bacterium and the dietary intakes in people with obesity: a randomized clinical trial. Appetite. 2019;141.","DOI":"10.1016\/j.appet.2019.05.032"},{"key":"1623_CR148","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.848450","volume":"9","author":"H Nonaka","year":"2022","unstructured":"Nonaka H, Ohue-Kitano R, Masujima Y, Igarashi M, Kimura I. Dietary medium-chain triglyceride decanoate affects glucose homeostasis through GPR84-mediated GLP-1 secretion in mice. Front Nutr. 2022;9: 848450.","journal-title":"Front Nutr"},{"key":"1623_CR149","doi-asserted-by":"crossref","unstructured":"Drzazga A, Kami\u0144ska D, Gliszczy\u0144ska A, Gendaszewska-Darmach E. Isoprenoid derivatives of lysophosphatidylcholines enhance insulin and GLP-1 secretion through lipid-binding GPCRs. Int J Mol Sci. 2021;22(11).","DOI":"10.3390\/ijms22115748"},{"issue":"2","key":"1623_CR150","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1021\/acsmedchemlett.6b00443","volume":"8","author":"CW Plummer","year":"2017","unstructured":"Plummer CW, Clements MJ, Chen H, Rajagopalan M, Josien H, Hagmann WK, et al. Design and synthesis of novel, selective GPR40 AgoPAMs. ACS Med Chem Lett. 2017;8(2):221\u20136.","journal-title":"ACS Med Chem Lett"},{"issue":"2","key":"1623_CR151","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.lfs.2013.11.010","volume":"94","author":"H Tanaka","year":"2014","unstructured":"Tanaka H, Yoshida S, Minoura H, Negoro K, Shimaya A, Shimokawa T, et al. Novel GPR40 agonist AS2575959 exhibits glucose metabolism improvement and synergistic effect with sitagliptin on insulin and incretin secretion. Life Sci. 2014;94(2):115\u201321.","journal-title":"Life Sci"},{"issue":"10","key":"1623_CR152","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1111\/1440-1681.13152","volume":"46","author":"H Tadaki","year":"2019","unstructured":"Tadaki H, Sasase T, Fukuda S, Toriniwa Y, Harada K, Ohta T, et al. Chronic treatment of JTP-109192, a novel G-protein coupled receptor 119 agonist, improves metabolic abnormalities in Zucker Fatty rats. Clin Exp Pharmacol Physiol. 2019;46(10):910\u20139.","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"3","key":"1623_CR153","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1124\/jpet.118.250019","volume":"367","author":"K Matsumoto","year":"2018","unstructured":"Matsumoto K, Yoshitomi T, Ishimoto Y, Tanaka N, Takahashi K, Watanabe A, et al. DS-8500a, an orally available G protein-coupled receptor 119 agonist, upregulates glucagon-like peptide-1 and enhances glucose-dependent insulin secretion and improves glucose homeostasis in type 2 diabetic rats. J Pharmacol Exp Ther. 2018;367(3):509\u201317.","journal-title":"J Pharmacol Exp Ther"},{"key":"1623_CR154","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111613","volume":"139","author":"G Bianchini","year":"2021","unstructured":"Bianchini G, Nigro C, Sirico A, Novelli R, Prevenzano I, Miele C, et al. A new synthetic dual agonist of GPR120\/GPR40 induces GLP-1 secretion and improves glucose homeostasis in mice. Biomed Pharmacother. 2021;139: 111613.","journal-title":"Biomed Pharmacother"},{"key":"1623_CR155","doi-asserted-by":"crossref","unstructured":"Kamakura R, Raza GS, M\u00e4kil\u00e4 E, Riikonen J, Kovalainen M, Ueta Y, et al. Colonic delivery of \u03b1-linolenic acid by an advanced nutrient delivery system prolongs glucagon-like peptide-1 secretion and inhibits food intake in mice. Mol Nutr Food Res. 2022;66(4).","DOI":"10.1002\/mnfr.202100978"},{"issue":"51","key":"1623_CR156","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.11.051","volume":"1","author":"M Gurung","year":"2020","unstructured":"Gurung M, Li Z, You H, Rodrigues R, Jump DB, Morgun A, et al. Role of gut microbiota in type 2 diabetes pathophysiology. EBioMedicine. 2020;1(51): 102590.","journal-title":"EBioMedicine"},{"issue":"6","key":"1623_CR157","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.jgr.2022.03.006","volume":"46","author":"F Tian","year":"2022","unstructured":"Tian F, Huang S, Xu W, Chen L, Su J, Ni H, et al. Compound K attenuates hyperglycemia by enhancing glucagon-like peptide-1 secretion through activating TGR5 via the remodeling of gut microbiota and bile acid metabolism. J Ginseng Res. 2022;46(6):780\u20139.","journal-title":"J Ginseng Res"},{"key":"1623_CR158","doi-asserted-by":"publisher","first-page":"109914","DOI":"10.1016\/j.biopha.2020.109914","volume":"125","author":"Y Wang","year":"2020","unstructured":"Wang Y, Dilidaxi D, Wu Y, Sailike J, Sun X, Nabi X. Composite probiotics alleviate type 2 diabetes by regulating intestinal microbiota and inducing GLP-1 secretion in db\/db mice. Biomed Pharmacother. 2020;125:109914.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"1623_CR159","doi-asserted-by":"publisher","first-page":"364","DOI":"10.2337\/db11-1019","volume":"61","author":"G Tolhurst","year":"2012","unstructured":"Tolhurst G, Heffron H, Lam YS, Parker HE, Habib AM, Diakogiannaki E, et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes. 2012;61(2):364\u201371.","journal-title":"Diabetes"},{"issue":"5","key":"1623_CR160","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41564-021-00880-5","volume":"6","author":"HS Yoon","year":"2021","unstructured":"Yoon HS, Cho CH, Yun MS, Jang SJ, You HJ, Kim JH, et al. Akkermansia muciniphila secretes a glucagon-like peptide-1-inducing protein that improves glucose homeostasis and ameliorates metabolic disease in mice. Nat Microbiol. 2021;6(5):563\u201373.","journal-title":"Nat Microbiol"},{"issue":"1","key":"1623_CR161","doi-asserted-by":"publisher","first-page":"79","DOI":"10.4149\/gpb_2019040","volume":"39","author":"F Huang","year":"2020","unstructured":"Huang F, Zhang L, Song X, Xu H, Wang F, Zhou L, et al. The effects of different concentrations of glucose on glucose sensors and GLP-1 secretion in the enteroendocrine cell line STC-1. Gen Physiol Biophys. 2020;39(1):79\u201387.","journal-title":"Gen Physiol Biophys"},{"key":"1623_CR162","doi-asserted-by":"crossref","unstructured":"Iwasaki Y, Sendo M, Dezaki K, Hira T, Sato T, Nakata M, et al. GLP-1 release and vagal afferent activation mediate the beneficial metabolic and chronotherapeutic effects of D-allulose. Nat Commun. 2018;9(1).","DOI":"10.1038\/s41467-017-02488-y"},{"key":"1623_CR163","doi-asserted-by":"publisher","first-page":"104310","DOI":"10.1016\/j.jff.2020.104310","volume":"76","author":"ZM Yang","year":"2021","unstructured":"Yang ZM, Wang Y, Chen SY. Astragalus polysaccharide alleviates type 2 diabetic rats by reversing the glucose transporters and sweet taste receptors\/GLP-1\/GLP-1 receptor signaling pathways in the intestine-pancreatic axis. J Funct Foods. 2021;76:104310.","journal-title":"J Funct Foods."},{"key":"1623_CR164","doi-asserted-by":"crossref","unstructured":"Kuang MT, Li JY, Yang XB, Yang L, Xu JY, Yan S, et al. Structural characterization and hypoglycemic effect via stimulating glucagon-like peptide-1 secretion of two polysaccharides from Dendrobium officinale. Carbohydr Polym. 2020;241.","DOI":"10.1016\/j.carbpol.2020.116326"},{"issue":"1","key":"1623_CR165","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1017\/S0007114514004322","volume":"114","author":"T Hira","year":"2015","unstructured":"Hira T, Ikee A, Kishimoto Y, Kanahori S, Hara H. Resistant maltodextrin promotes fasting glucagon-like peptide-1 secretion and production together with glucose tolerance in rats. Br J Nutr. 2015;114(1):34\u201342.","journal-title":"Br J Nutr"},{"issue":"1","key":"1623_CR166","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1093\/bbb\/zbac171","volume":"87","author":"K Mio","year":"2022","unstructured":"Mio K, Togo-Ohno M, Tadenuma N, Ogawa R, Yamanaka C, Aoe S. A single administration of barley \u03b2-glucan and arabinoxylan extracts reduces blood glucose levels at the second meal via intestinal fermentation. Biosci Biotechnol Biochem. 2022;87(1):99\u2013107.","journal-title":"Biosci Biotechnol Biochem"},{"issue":"4","key":"1623_CR167","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3177\/jnsv.67.217","volume":"67","author":"K Honda","year":"2021","unstructured":"Honda K, Yasuhara A, Saneyasu T, Kamisoyama H. Enzymatically-synthesized glycogen induces cecal glucagon-like peptide-1 production and suppresses food intake in mice. J Nutr Sci Vitaminol (Tokyo). 2021;67(4):217\u201324.","journal-title":"J Nutr Sci Vitaminol (Tokyo)"},{"issue":"3","key":"1623_CR168","doi-asserted-by":"publisher","first-page":"E417","DOI":"10.1152\/ajpendo.00071.2021","volume":"321","author":"L Le Gl\u00e9au","year":"2021","unstructured":"Le Gl\u00e9au L, Rouault C, Osinski C, Prifti E, Soula HA, Deb\u00e9dat J, et al. Intestinal alteration of \u03b1-gustducin and sweet taste signaling pathway in metabolic diseases is partly rescued after weight loss and diabetes remission. Am J Physiol Endocrinol Metab. 2021;321(3):E417\u201332.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"8","key":"1623_CR169","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.2337\/db17-0058","volume":"66","author":"EW Sun","year":"2017","unstructured":"Sun EW, De Fontgalland D, Rabbitt P, Hollington P, Sposato L, Due SL, et al. Mechanisms controlling glucose-induced GLP-1 secretion in human small intestine. Diabetes. 2017;66(8):2144\u20139.","journal-title":"Diabetes"},{"issue":"4","key":"1623_CR170","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaim.2019.06.003","volume":"11","author":"PK Bhateja","year":"2020","unstructured":"Bhateja PK, Kajal A, Singh R. Amelioration of diabetes mellitus by modulation of GLP-1 via targeting alpha-glucosidase using Acacia tortilis polysaccharide in Streptozotocin-Nicotinamide induced diabetes in rats. J Ayurveda Integr Med. 2020;11(4):405\u201313.","journal-title":"J Ayurveda Integr Med."},{"key":"1623_CR171","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.bbrc.2022.06.069","volume":"621","author":"Y Ma","year":"2022","unstructured":"Ma Y, Lee E, Yoshikawa H, Noda T, Miyamoto J, Kimura I, et al. Phloretin suppresses carbohydrate-induced GLP-1 secretion via inhibiting short chain fatty acid release from gut microbiome. Biochem Biophys Res Commun. 2022;621:176\u201382.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"1623_CR172","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s13300-015-0113-3","volume":"6","author":"H Ueno","year":"2015","unstructured":"Ueno H, Tsuchimochi W, Wang HW, Yamashita E, Tsubouchi C, Nagamine K, et al. Effects of miglitol, acarbose, and sitagliptin on plasma insulin and gut peptides in type 2 diabetes mellitus: a crossover study. Diabetes Ther. 2015;6(2):187\u201396.","journal-title":"Diabetes Ther."},{"key":"1623_CR173","doi-asserted-by":"publisher","first-page":"104222","DOI":"10.1016\/j.jff.2020.104222","volume":"75","author":"W Zhou","year":"2020","unstructured":"Zhou W, Chen G, Chen D, Ye H, Zeng X. The antidiabetic effect and potential mechanisms of natural polysaccharides based on the regulation of gut microbiota. J Funct Foods. 2020;75:104222.","journal-title":"J Funct Foods."},{"issue":"2","key":"1623_CR174","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1124\/jpet.113.203364","volume":"345","author":"DR Powell","year":"2013","unstructured":"Powell DR, Smith M, Greer J, Harris A, Zhao S, DaCosta C, et al. LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium\/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose. J Pharmacol Exp Ther. 2013;345(2):250\u20139.","journal-title":"J Pharmacol Exp Ther"},{"key":"1623_CR175","doi-asserted-by":"crossref","unstructured":"Trabelsi MS, Daoudi M, Prawitt J, Ducastel S, Touche V, Sayin SI, et al. Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells. Nat Commun. 2015;6.","DOI":"10.1038\/ncomms8629"},{"issue":"8","key":"1623_CR176","doi-asserted-by":"publisher","first-page":"12839","DOI":"10.1002\/jcp.27940","volume":"234","author":"P Li","year":"2019","unstructured":"Li P, Zhu L, Yang X, Li W, Sun X, Yi B, et al. Farnesoid X receptor interacts with cAMP response element binding protein to modulate glucagon-like peptide-1 (7\u201336) amide secretion by intestinal L cell. J Cell Physiol. 2019;234(8):12839\u201346.","journal-title":"J Cell Physiol"},{"issue":"5","key":"1623_CR177","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/dom.12043","volume":"15","author":"T Wu","year":"2013","unstructured":"Wu T, Bound MJ, Standfield SD, Gedulin B, Jones KL, Horowitz M, et al. Effects of rectal administration of taurocholic acid on glucagon-like peptide-1 and peptide YY secretion in healthy humans. Diabetes Obes Metab. 2013;15(5):474\u20137.","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"1623_CR178","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1007\/s00125-012-2593-2","volume":"55","author":"TE Adrian","year":"2012","unstructured":"Adrian TE, Gariballa S, Parekh KA, Thomas SA, Saadi H, Al Kaabi J, et al. Rectal taurocholate increases L cell and insulin secretion, and decreases blood glucose and food intake in obese type 2 diabetic volunteers. Diabetologia. 2012;55(9):2343\u20137.","journal-title":"Diabetologia"},{"issue":"6","key":"1623_CR179","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/dom.12648","volume":"18","author":"M Hansen","year":"2016","unstructured":"Hansen M, Scheltema MJ, Sonne DP, Hansen JS, Sperling M, Rehfeld JF, et al. Effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagon-like peptide-1 secretion. Diabetes Obes Metab. 2016;18(6):571\u201380.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"1623_CR180","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.cmet.2009.08.001","volume":"10","author":"C Thomas","year":"2009","unstructured":"Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 2009;10(3):167.","journal-title":"Cell Metab"},{"key":"1623_CR181","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.metabol.2019.07.003","volume":"99","author":"S Huang","year":"2019","unstructured":"Huang S, Ma S, Ning M, Yang W, Ye Y, Zhang L, et al. TGR5 agonist ameliorates insulin resistance in the skeletal muscles and improves glucose homeostasis in diabetic mice. Metabolism. 2019;99:45\u201356.","journal-title":"Metabolism"},{"issue":"10","key":"1623_CR182","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/j.bmcl.2018.04.011","volume":"28","author":"S Agarwal","year":"2018","unstructured":"Agarwal S, Sasane S, Kumar J, Deshmukh P, Bhayani H, Giri P, et al. Evaluation of novel TGR5 agonist in combination with Sitagliptin for possible treatment of type 2 diabetes. Bioorg Med Chem Lett. 2018;28(10):1849\u201352.","journal-title":"Bioorg Med Chem Lett"},{"issue":"1","key":"1623_CR183","first-page":"1","volume":"2","author":"T Harach","year":"2012","unstructured":"Harach T, Pols TWH, Nomura M, Maida A, Watanabe M, Auwerx J, et al. TGR5 potentiates GLP-1 secretion in response to anionic exchange resins. Sci Reports. 2012;2(1):1\u20137.","journal-title":"Sci Reports"},{"issue":"4","key":"1623_CR184","doi-asserted-by":"publisher","first-page":"G371","DOI":"10.1152\/ajpgi.00400.2012","volume":"304","author":"MJ Potthoff","year":"2013","unstructured":"Potthoff MJ, Potts A, He T, Duarte JAG, Taussig R, Mangelsdorf DJ, et al. Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice. Am J Physiol Gastrointest Liver Physiol. 2013;304(4):G371.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"3","key":"1623_CR185","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1152\/ajpgi.00362.2009","volume":"298","author":"Q Shang","year":"2010","unstructured":"Shang Q, Saumoy M, Holst JJ, Salen G, Xu G. Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1. Am J Physiol Gastrointest Liver Physiol. 2010;298(3):419.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"2","key":"1623_CR186","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/dom.13080","volume":"20","author":"A Br\u00f8nden","year":"2018","unstructured":"Br\u00f8nden A, Alb\u00e9r A, Rohde U, Gasbjerg LS, Rehfeld JF, Holst JJ, et al. The bile acid-sequestering resin sevelamer eliminates the acute GLP-1 stimulatory effect of endogenously released bile acids in patients with type 2 diabetes. Diabetes Obes Metab. 2018;20(2):362\u20139.","journal-title":"Diabetes Obes Metab"},{"key":"1623_CR187","doi-asserted-by":"crossref","unstructured":"Avila JAD, Garc\u00eda JR, Aguilar GAG, De La Rosa LA. The Antidiabetic mechanisms of polyphenols related to increased glucagon-like peptide-1 (GLP1) and insulin signaling. Molecules. 2017;22(6).","DOI":"10.3390\/molecules22060903"},{"key":"1623_CR188","doi-asserted-by":"crossref","unstructured":"Wang Y, Alkhalidy H, Liu D. The emerging role of polyphenols in the management of type 2 diabetes. Molecules. 2021;26(3).","DOI":"10.3390\/molecules26030703"},{"issue":"5","key":"1623_CR189","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126157","volume":"10","author":"M Kato","year":"2015","unstructured":"Kato M, Tani T, Terahara N, Tsuda T. The anthocyanin delphinidin 3-rutinoside stimulates glucagon-like peptide-1 secretion in murine GLUTag cell line via the Ca2+\/calmodulin-dependent kinase II pathway. PLoS ONE. 2015;10(5): e0126157.","journal-title":"PLoS ONE"},{"issue":"6","key":"1623_CR190","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1093\/jn\/nxab029","volume":"151","author":"E Cremonini","year":"2021","unstructured":"Cremonini E, Daveri E, Mastaloudis A, Oteiza PI. (\u2013)-Epicatechin and anthocyanins modulate GLP-1 metabolism: evidence from C57BL\/6J mice and GLUTag cells. J Nutr. 2021;151(6):1497\u2013506.","journal-title":"J Nutr"},{"key":"1623_CR191","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.108670","volume":"112","author":"K Rehman","year":"2019","unstructured":"Rehman K, Ali MB, Akash MSH. Genistein enhances the secretion of glucagon-like peptide-1 (GLP-1) via downregulation of inflammatory responses. Biomed Pharmacother. 2019;112: 108670.","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"1623_CR192","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.3390\/ijms24043682","volume":"24","author":"SH Lee","year":"2023","unstructured":"Lee SH, Ko HM, Jee W, Kim H, Chung WS, Jang HJ. Isosinensetin stimulates glucagon-like peptide-1 secretion via activation of hTAS2R50 and the G(\u03b2\u03b3)-mediated signaling pathway. Int J Mol Sci. 2023;24(4):3682.","journal-title":"Int J Mol Sci"},{"issue":"1\u20132","key":"1623_CR193","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11010-018-3290-3","volume":"447","author":"X Yue","year":"2018","unstructured":"Yue X, Liang J, Gu F, Du D, Chen F. Berberine activates bitter taste responses of enteroendocrine STC-1 cells. Mol Cell Biochem. 2018;447(1\u20132):21\u201332.","journal-title":"Mol Cell Biochem"},{"key":"1623_CR194","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.3389\/fphar.2018.01071","volume":"9","author":"KH Kim","year":"2018","unstructured":"Kim KH, Lee IS, Park JY, Kim Y, An EJ, Jang HJ. Cucurbitacin B induces hypoglycemic effect in diabetic mice by regulation of AMP-activated protein kinase alpha and glucagon-like peptide-1 via bitter taste receptor signaling. Front Pharmacol. 2018;9:1071.","journal-title":"Front Pharmacol"},{"issue":"10","key":"1623_CR195","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1007\/s00125-014-3326-5","volume":"57","author":"KS Kim","year":"2014","unstructured":"Kim KS, Egan JM, Jang HJ. Denatonium induces secretion of glucagon-like peptide-1 through activation of bitter taste receptor pathways. Diabetologia. 2014;57(10):2117\u201325.","journal-title":"Diabetologia"},{"issue":"4","key":"1623_CR196","doi-asserted-by":"publisher","first-page":"E537","DOI":"10.1152\/ajpendo.00046.2024","volume":"326","author":"W Huang","year":"2024","unstructured":"Huang W, O\u2019Hara SE, Xie C, Liu N, Rayner CK, Nicholas LM, et al. Effects of a bitter substance, denatonium benzoate, on pancreatic hormone secretion. Am J Physiol Endocrinol Metab. 2024;326(4):E537\u201344. https:\/\/doi.org\/10.1152\/ajpendo.00046.2024.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"6","key":"1623_CR197","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1093\/jn\/nxab020","volume":"151","author":"BD Rose","year":"2021","unstructured":"Rose BD, Bitarafan V, Rezaie P, Fitzgerald PCE, Horowitz M, Feinle-Bisset C. Comparative effects of intragastric and intraduodenal administration of quinine on the plasma glucose response to a mixed-nutrient drink in healthy men: relations with glucoregulatory hormones and gastric emptying. J Nutr. 2021;151(6):1453\u201361.","journal-title":"J Nutr"},{"issue":"1","key":"1623_CR198","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1172\/JCI75838","volume":"125","author":"N Petersen","year":"2015","unstructured":"Petersen N, Reimann F, van Es JH, van den Berg BM, Kroone C, Pais R, et al. Targeting development of incretin-producing cells increases insulin secretion. J Clin Invest. 2015;125(1):379\u201385.","journal-title":"J Clin Invest"},{"issue":"2","key":"1623_CR199","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.stem.2016.11.001","volume":"20","author":"O Basak","year":"2017","unstructured":"Basak O, Beumer J, Wiebrands K, Seno H, van Oudenaarden A, Clevers H. Induced quiescence of Lgr5+ stem cells in intestinal organoids enables differentiation of hormone-producing enteroendocrine cells. Cell Stem Cell. 2017;20(2):177-190e4. https:\/\/doi.org\/10.1016\/j.stem.2016.11.001.","journal-title":"Cell Stem Cell"},{"issue":"2","key":"1623_CR200","doi-asserted-by":"publisher","first-page":"410","DOI":"10.2337\/db13-0991","volume":"63","author":"N Petersen","year":"2014","unstructured":"Petersen N, Reimann F, Bartfeld S, Farin HF, Ringnalda FC, Vries RGJ, et al. Generation of L-cells in mouse and human small intestine organoids. Diabetes. 2014;63(2):410.","journal-title":"Diabetes"},{"issue":"4","key":"1623_CR201","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1053\/j.gastro.2018.06.039","volume":"155","author":"N Petersen","year":"2018","unstructured":"Petersen N, Frimurer TM, Terndrup Pedersen M, Egerod KL, Wewer Albrechtsen NJ, Holst JJ, et al. Inhibiting RHOA signaling in mice increases glucose tolerance and numbers of enteroendocrine and other secretory cells in the intestine. Gastroenterology. 2018;155(4):1164-1176e2.","journal-title":"Gastroenterology"},{"key":"1623_CR202","doi-asserted-by":"crossref","unstructured":"Kim KS, Jung Yang H, Lee IS, Kim KH, Park J, Jeong HS, et al. The aglycone of ginsenoside Rg3 enables glucagon-like peptide-1 secretion in enteroendocrine cells and alleviates hyperglycemia in type 2 diabetic mice. Sci Rep. 2015;5.","DOI":"10.1038\/srep18325"},{"key":"1623_CR203","first-page":"113","volume":"1","author":"F Tian","year":"2022","unstructured":"Tian F, Xu W, Chen L, Chen T, Feng X, Chen J, et al. Ginsenoside compound K increases glucagon-like peptide-1 release and L-cell abundance in db\/db mice through TGR5\/YAP signaling. Int Immunopharmacol. 2022;1:113.","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"1623_CR204","doi-asserted-by":"publisher","first-page":"614","DOI":"10.2337\/db19-0764","volume":"69","author":"ML Lund","year":"2020","unstructured":"Lund ML, Sorrentino G, Egerod KL, Kroone C, Mortensen B, Knop FK, et al. L-cell differentiation is induced by bile acids through GPBAR1 andparacrine GLP-1 and serotonin signaling. Diabetes. 2020;69(4):614.","journal-title":"Diabetes"},{"issue":"9","key":"1623_CR205","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.chembiol.2022.08.001","volume":"29","author":"L Chu","year":"2022","unstructured":"Chu L, Terasaki M, Mattsson CL, Teinturier R, Charbord J, Dirice E, et al. In vivo drug discovery for increasing incretin-expressing cells identifies DYRK inhibitors that reinforce the enteroendocrine system. Cell Chem Biol. 2022;29(9):1368-1380.e5.","journal-title":"Cell Chem Biol"},{"issue":"6","key":"1623_CR206","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.jcmgh.2023.08.006","volume":"16","author":"M Miura","year":"2023","unstructured":"Miura M, Igarashi M, Isotani R, Nakagawa-Nagahama Y, Kuranami S, Naruse K, et al. SIRT1 controls enteroendocrine progenitor cell proliferation in high-fat diet-fed mice. Cell Mol Gastroenterol Hepatol. 2023;16(6):1040.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"6","key":"1623_CR207","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1038\/s42255-023-00811-0","volume":"5","author":"K El","year":"2023","unstructured":"El K, Douros JD, Willard FS, Novikoff A, Sargsyan A, Perez-Tilve D, et al. The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets. Nat Metab. 2023;5(6):945\u201354.","journal-title":"Nat Metab"}],"container-title":["Diabetology &amp; Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-025-01623-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-025-01623-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-025-01623-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T17:35:30Z","timestamp":1739813730000},"score":1,"resource":{"primary":{"URL":"https:\/\/dmsjournal.biomedcentral.com\/articles\/10.1186\/s13098-025-01623-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,17]]},"references-count":207,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1623"],"URL":"https:\/\/doi.org\/10.1186\/s13098-025-01623-w","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,17]]},"assertion":[{"value":"22 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"60"}}